Number: 1 68Ga-PSMA PET/CT in staging and restaging of Prostate Cancer Patients: comparative study with 18FCholine PET/CT W. Langsteger1, A. Rezaee1, W. Loidl2, H.s Geinitz3, F. Fitz1, M. Steinmair1, G. Broinger4, L. Pallwien-Prettner5, M. Beheshti1. 1 PET-CT Center Linz, Department of Nuclear Medicine & Endocrinology, 2 Prostate Cancer Center Linz, Department of Urology,3 Department of Radiati...

BACKGROUND Labelling proteins with gallium-68 using bifunctional chelators is often problematic because of unsuitably harsh labelling conditions such as low pH or high temperature and may entail post-labelling purification. To determine whether tris(hydroxypyridinone) (THP) bifunctional chelators offer a potential solution to this problem, we have evaluated the labelling and biodistribution of ...

La estimación del puntaje Gleason (PG) en pacientes con cáncer de próstata (PCa) mediante modelos radiómicos es especial interés por ser una alternativa no invasiva a la biopsia, para estratificar el nivel riesgo y ayudar elección tratamiento. Nuestro objetivo estimar PG un modelo radiómico imágenes [68Ga]-antígeno membrana específico (PSMA, Prostate Specific Membrane Antigen) tomografía emisió...

Objective To assess the activity and safety of sequential lutetium-177 (177Lu)-PSMA-617 docetaxel vs on a background androgen deprivation therapy (ADT) in men with de novo metastatic hormone-naïve prostate cancer (mHNPC). Patients Methods UpFrontPSMA (NCT04343885) is an open-label, randomized, multicentre, phase 2 trial, recruiting 140 patients at 12 Australian centres. Key eligibility criteria...

Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate...

Introducción y objetivo: Los subtipos histológicos agresivos de cáncer tiroides son menos frecuentes tienen peor pronóstico que los bien diferenciados (CDT). más importantes el carcinoma células Hürthle (CCH), anaplásico pobremente diferenciado En esta revisión vamos a hablar del papel PET-CT, especialmente con 18F-FDG, en estas estirpes histológicas agresivas, así como CDT (células altas, escl...

BACKGROUND While 68Ga-PSMA PET-MRI might be superior to PET-CT with regard to soft tissue assessment in prostate cancer evaluation, it is also known to potentially introduce additional PET image artefacts. Therefore, the impact of PET acquisition duration and attenuation data on artefact occurrence, lesion detectability, and quantification was investigated. To this end, whole-body PET list mode...

PURPOSE Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate canc...

Recently, Torricelli et al. (1) published a video showing a step by step technique for salvage lymph node dissection after radical prostatectomy. With the development of novel imaging techniques, the identification of PCa patients with a clinical lymphonode (LN) relapse has become feasible. Salvage LN dissection (SLND) represents a treatment option for patients with prostate cancer relapse limi...